AstraZeneca shares fell on Wednesday after European regulators discovered a possible link between the company’s Covid vaccine and rare cases of blood clots.
The Safety Committee of the European Medicines Agency reviewed 62 and 24 cases of blood clots in the brain and abdomen, respectively. People have reported cases to systems in Europe and the UK, where approximately 25 million people have received the two-dose vaccine.
He concluded that unusual blood clots with a low platelet count should be attributed to very rare side effects. AstraZeneca(AZN) Covid vaccine. To date, most cases have occurred in women under 60 years of age within two weeks of immunization. The agency reaffirmed its belief that the benefits of vaccination against Covid outweigh the risks.
“One plausible explanation for the combination of blood clots and low platelet counts is an immune response leading to a condition similar to that sometimes seen in patients treated with heparin,” the EMA wrote in its report.
On the stock market today, AstraZeneca shares fell 1.6% to 48.42.
AstraZeneca stock falls into the new vaccine category
The news came as a blow to the stock of AstraZeneca and Vaccine, a partner at Oxford University.
Pending further details, Oxford researchers have suspended research on a vaccine in children and adolescents in the UK, the Wall Street Journal reported on Tuesday.
The vaccine has raised many concerns over the past year.
Most recently, a vaccine proved 76% effective against symptomatic Covid-19 in a late-stage US study. But before that, the independent data and security control board suggested that the company included outdated data in its analysis.
Earlier reports of blood clots in vaccine recipients prompted several European countries to suspend the introduction of the AstraZeneca vaccine. Earlier this year, researchers said the vaccine offered minimal protection against a variant first identified in South Africa.
Overall, AstraZeneca shares are down 2.5% this year as of Wednesday afternoon.
J&J Vaccine Faces More Confusion
Also on Wednesday, the New York Times reported 62 million doses Johnson and Johnson(JNJ) Covid vaccine may have been contaminated during a confusion at a production site operated by New biosolutions (EBS).
Emergent is working on Covid vaccines for both Johnson & Johnson and AstraZeneca. Earlier this year, workers at a Baltimore facility combined ingredients for two vaccines, ruining 15 million doses of J&J.
62 million additional doses now need to be rechecked to make sure none of them have been cross-contaminated, according to the New York Times.
Emergent said Monday it has received an additional $ 23 million from the Advanced Biomedical Research and Development Agency to purchase additional equipment needed to make the Johnson & Johnson injection.
The company also noted “additional control and support” at its Baltimore plant. This includes the “reinforcement and final approval” of the Johnson & Johnson shot.
Follow Allison Gatlin on Twitter at @IBD_AGatlin…
YOU MAY ALSO LIKE:
FibroGen Crashes Following Safety Data Analysis for Controversial Drug
Biohaven’s forecasts; What’s next for his hopeful blockbuster?
Options trading: how to start using options, how to manage risk
Looking for the next big stock market winners? Get started with these three steps
Do you want to make quick profits and avoid big losses? Try SwingTrader